Additionally, only these strictly IA-2(256–760) autoantibody-positive T2DM patients phenotypically resembled patients who are obese with T2DM and have a longer time without the need for insulin treatment over 7 years compared to GAD autoantibody-positive patients [119]. This evidence concerns the gene GAD1 and type 2 diabetes mellitus.